Literature DB >> 27764706

Management of postoperative pain after Lumbar surgery-pregabalin for one day and 14 days-a randomized, triple-blinded, placebo-controlled study.

Mohammad Zarei1, Arvin Najafi2, Pejman Mansouri1, Sadaf Sadeghi-Yazdankhah3, Houshang Saberi3, Mehran Moradi3, Mahmoud Farzan1.   

Abstract

OBJECTIVES: Despite the progress in understanding acute pain physiology during recent decade, eighty percent of patients still suffer from post-operative discomfort. Pregabalin is an anticonvulsant agent that is approved for painful neuropathies in diabetic patients and post herpetic neuralgia. The main objective of the present study was to compare the improvement in post-operative pain management and patient lifestyle in 3 groups, as first group received placebo, second who received Pregabalin for one day and the last group those who received it for 14 days.
METHODS: This was a prospective single center, randomized, triple-blind, 3-arm, parallel group study. In this triple-blind study, patients were randomized to 1 of 3 groups using computer-generated random number table. 1) The first group received placebo for 14 days, the second group received Pregabalin 300mg 8h preoperatively and 150mg 12 and 24h postoperatively and for the rest of 13days received placebo and the third group received Pregabalin 300mg eight hours preoperatively and 15mg every 12h postoperatively for 14 days. Name, age, gender, height, weight, education, duration of pain, past medical history, drug history,total morphine requirement at the time of discharge and MRI findings of all the patients were recorded, also they Numerical scale system (NRS) and Oswestry low back pain disability index (ODI) questionnaire were completed for them. All the patients were operated based on standard surgery techniques, bilateral foramenotomy and interlaminar discectomy.
RESULTS: Of the 105 patients who entered the run-in period, 47 patients (44.8%) were female and 58 (55.2%) were male. The Patients radicular pain mean score based on NRS estimated before surgery was 7.22±1.95 in pregabalin14, 7.71±1.84 in pregabalin1 and 7.45±1.9 in control group. There were no statically significant differences between three groups (P-Value>0.05). The Patients back pain mean score based on NRS was 5.2±2.87 in pregabalin14, 5.11±3.23 in pregabalin1 and 6.4±3.06 in control group. This means that there were no significant differences in the overall score among those three groups (P-Value>0.05). In comparison to their preoperative pain, the average radicular pain in each group of patients improved significantly 4, 8, 12 and 24h after the operation (P-Value<0.001), but there were no significant differences in radicular pain improvements comparing three groups.
CONCLUSION: The results of this study indicate that 1day and 2 weeks post-operative 300mg pregabalin administration may not improve acute pain, morphine consumption and quality of life of patients after surgery. It seems that the diseases cause chronic pain that requires long-term treatment with higher doses. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Discectomy; Morphine; Postoperative pain; Pregabalin; Quality of life

Mesh:

Substances:

Year:  2016        PMID: 27764706     DOI: 10.1016/j.clineuro.2016.10.007

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Pregabalin treatment for neuropathic pain may damage intervertebral disc tissue.

Authors:  Numan Karaarslan; Ibrahim Yilmaz; Duygu Yasar Sirin; Hanefi Ozbek; Necati Kaplan; Yasin Emre Kaya; Yener Akyuva; Mehmet Sabri Gurbuz; Kadir Oznam; Ozkan Ates
Journal:  Exp Ther Med       Date:  2018-06-12       Impact factor: 2.447

2.  Transforming Standard of Care for Spine Surgery: Integration of an Online Single-Session Behavioral Pain Management Class for Perioperative Optimization.

Authors:  Sara A Davin; Jason Savage; Nicholas R Thompson; Andrew Schuster; Beth D Darnall
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.